Mirum Pharmaceuticals (MEX:MIRM) Other Current Liabilities: MXN1,104 Mil (As of Mar. 2026)


MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
46 GF Score
Price MXN1,256.12
GF Value MXN849.96
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Other Current Liabilities?

Mirum Pharmaceuticals MEX:MIRM 46 Other Current Liabilities is MXN1,104 Mil as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN849.96. The stock has 6 warning signs investors should review.

Mirum Pharmaceuticals's other current liabilities for the quarter that ended in Mar. 2026 was MXN1,104 Mil.

Mirum Pharmaceuticals's quarterly other current liabilities increased from Sep. 2025 (MXN678 Mil) to Dec. 2025 (MXN851 Mil) and increased from Dec. 2025 (MXN851 Mil) to Mar. 2026 (MXN1,104 Mil).

Mirum Pharmaceuticals's annual other current liabilities increased from Dec. 2023 (MXN355 Mil) to Dec. 2024 (MXN673 Mil) and increased from Dec. 2024 (MXN673 Mil) to Dec. 2025 (MXN851 Mil).

Mirum Pharmaceuticals Other Current Liabilities Related Terms

Mirum Pharmaceuticals Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Other Current Liabilities Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 245.84 307.06 355.42 672.56 851.24

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 339.59 505.34 678.39 851.24 1,104.18
MEX:MIRM
46GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN1,104 Mil mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Other Current Liabilities of MXN1,104 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mirum Pharmaceuticals.
Is Mirum Pharmaceuticals' Other Current Liabilities too high?
Mirum Pharmaceuticals' current Other Current Liabilities is MXN1,104 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Other Current Liabilities compare to RYTM and SYRE?
Mirum Pharmaceuticals' Other Current Liabilities of MXN1,104 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mirum Pharmaceuticals. Mirum Pharmaceuticals's current Other Current Liabilities is MXN1,104 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Other Current Liabilities of MXN1,104 Mil. The stock's GF Value™ is MXN849.96, compared to a current price of MXN1,256.12 — trading 47.8% above its estimated fair value. The current Other Current Liabilities is MXN1,104 Mil. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Other Current Liabilities is MXN1,104 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 47.8% above its estimated GF Value™ of MXN849.96.

Key valuation signals for MEX:MIRM:

  • Other Current Liabilities: MXN1,104 Mil
  • GF Value™: MXN849.96 vs. price of MXN1,256.12 (47.8% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score

Get the complete analysis for MEX:MIRM

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN849.96
GF Value